SOPHiA GENETICS SA - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of January 2026, with a report date of January 28, 2026. SOPHiA GENETICS SA, a Swiss-based foreign private issuer, reports on a material amendment to its existing credit facility and associated warrant agreements.
Key Financial Metrics and Capital Structure
The filing details a significant expansion of the Company's debt capacity and equity-linked obligations:
- Debt Capacity: An additional $25 million in term loan commitments was added to the Perceptive Credit Agreement.
- Tranche C: $12.5 million available immediately subject to customary conditions.
- Tranche D: $12.5 million contingent on the Company achieving trailing twelve-month revenue exceeding $85 million.
- Interest Rate: Term SOFR + 6.25% per annum.
- Maturity: 2029.
- Warrant Issuance: The lender received rights to purchase up to 275,000 ordinary shares in total (75,000 immediately exercisable; 100,000 upon Tranche C drawdown; 100,000 upon Tranche D drawdown).
The filing text does not provide specific values for current revenue, profit, cash flow, or existing debt balances as of the reporting date.
Material Changes
The primary material change is the execution of the "Second Amendment" to the credit agreement dated May 2, 2024. This amendment increases the total committed credit facility by $25 million and introduces a revenue-based milestone for the final tranche. Additionally, the Warrant Certificate was amended and restated to accommodate the new equity purchase rights for the lender.
Outlook, Risks, and Management Commentary
Outlook: The structure of the Tranche D loan implies management's expectation or target of reaching $85 million in trailing twelve-month revenue to unlock the full $25 million commitment.
Risks and Contingencies:
- Revenue Milestone: Access to $12.5 million of the new funding is contingent on meeting specific revenue thresholds.
- Dilution: The issuance of warrants for up to 275,000 shares represents potential future dilution to existing shareholders.
- Registration Obligations: The Company is required to file registration statements within 30 business days of each warrant tranche becoming available and maintain their effectiveness until shares are sold or eligible for public sale.
Investor Verification Checklist
- Verify the Company's current trailing twelve-month revenue to assess the likelihood of drawing Tranche D.
- Review the full text of Exhibit 99.1 (Second Amendment) for specific covenants and customary conditions attached to the Tranche C drawdown.
- Confirm the current outstanding balance of the original Perceptive Credit Agreement to calculate total leverage post-amendment.
- Monitor upcoming filings for the required registration statements related to the new warrant tranches.